+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Evaluation of [18F]fluoroxanomeline {5-{4-[(6-[18F]fluorohexyl)oxy]-1,2,5-thiadiazol-3-yl}-1-methyl-1,2,3,6-tetrahydropyridine} in muscarinic knockout mice



Evaluation of [18F]fluoroxanomeline {5-{4-[(6-[18F]fluorohexyl)oxy]-1,2,5-thiadiazol-3-yl}-1-methyl-1,2,3,6-tetrahydropyridine} in muscarinic knockout mice



Nuclear Medicine and Biology 34(2): 141-152



We set out to develop a muscarinic M1-selective agonist (based on the structure of the functionally M1-selective xanomeline) that could be radiolabeled with fluorine-18 for use as an imaging agent for positron emission tomography. The radiochemical synthesis was achieved, employing the arts of organic and radiochemical syntheses. Binding selectivity studies employed biodistribution studies, using autoradiography and/or tissue dissection, in wild-type or muscarinic receptor knockout mice. [(18)F]Fluoroxanomeline shows rather uniform uptake in all mouse brain regions and high specific binding, with a brain-to-blood ratio of 32 at 60 min postinjection. In addition, the specific binding is demonstrated by a 58% to 75% decrease in brain uptake upon coinjection with 5 nmol of unlabeled fluoroxanomeline or xanomeline. Brain uptake studies with [(3)H]xanomeline in muscarinic knockout mice show decreased uptake in M1 (17-34%) and M2 (2-20%) knockout mice compared with control. However, statistical significance was observed in only a few regions. Comparison of [(18)F]fluoroxanomeline in knockout mice showed no difference in M1 or M4 knockout mice but a general decrease in M2 (2-24%) knockout mice. The decrease of [(18)F]fluoroxanomeline uptake in M2 knockout mice reached statistical significance in brain stem, cerebellum, frontal cortex, hippocampus, inferior colliculus and superior colliculus. Although xanomeline displays highly selective M1 agonist activity in functional assays, little selectivity for muscarinic subtype binding was observed for xanomeline or its fluorine-containing analogue, fluoroxanomeline. This emphasizes the lack of correlation between functional selectivity and binding selectivity.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 048993179

Download citation: RISBibTeXText

PMID: 17307122

DOI: 10.1016/j.nucmedbio.2006.11.002


Related references

Design and synthesis of novel derivatives of the muscarinic agonist tetra(ethylene glycol)(3-methoxy-1,2,5-thiadiazol-4-yl) [3-(1-methyl-1,2,5,6-tetrahydropyrid-3-yl)-1,2,5-thiadiazol-4-yl] ether (CDD-0304): effects of structural modifications on the binding and activity at muscarinic receptor subtypes and chimeras. Journal of Medicinal Chemistry 49(25): 7518-7531, 2006

Synthesis of 5- thiadiazol-3-yl-3-methyl-1,2,3,4-tetrahydropyrimidine oxalate salts and their evaluation as muscarinic receptor agonists. Archiv der Pharmazie (Weinheim) 336(4-5): 230-235, 2003

Synthesis of 5-(4-alkylsulfanyl-[1, 2, 5]thiadiazol-3-yl)-3-methyl-1, 2, 3, 4-tetrahydropyrimidine oxalate salts and their evaluation as muscarinic receptor agonists. Archiv der Pharmazie 336(4-5): 230-235, 2003

Synthesis of 5-(4-alkoxy-[1,2,5]thiadiazol-3-yl)-3-methyl-1,2,3,4-tetrahydropyrimidi ne oxalate salts and their evaluation as muscarinic receptor agonists. Archiv der Pharmazie 333(5): 113-117, 2000

Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice. European Journal of Pharmacology 603(1-3): 147-149, 2009

Evaluation of muscarinic agonist-induced analgesia in muscarinic receptor knockout mice. Life Sciences 68(22-23): 2631, 2001

Evaluation of muscarinic agonist-induced analgesia in muscarinic acetylcholine receptor knockout mice. Molecular Pharmacology 62(5): 1084-1093, 2002

Parkin-knockout mice did not display increased vulnerability to intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neurotoxicity Research 24(2): 280-287, 2013

Synthesis of 1-methyl-5-(pyrazol-3- and -5-yl- and 1, 2, 4-triazol-3- and 5-yl)-1, 2, 3, 6-tetrahydropyridine derivatives and their evaluation as muscarinic receptor ligands. Archiv der Pharmazie 336(3): 143-154, 2003

Pituitary-adrenal responses to oxotremorine and acute stress in male and female M1 muscarinic receptor knockout mice: comparisons to M2 muscarinic receptor knockout mice. Journal of Neuroendocrinology 20(5): 617-625, 2008

Methyl 4 2 methylphenyl 1 2 3 6 tetrahydropyridine is a more potent dopaminergic neurotoxin than 1 methyl 4 phenyl 1 2 3 6 tetrahydropyridine in mice. European Journal Of Pharmacology: 283-287, 1986

Effect of 4-(4-methoxy-1,2,5-thiadiazol-3-yl)-1-methyl-1,2,3,6-tetrahydropyridine, an analog of MPTP, on mouse heart norepinephrine and brain catecholamines. Neurochemistry International 23(5): 467-470, 1993

Comparison of the effects of two 1 methyl 4 phenyl 1 2 3 6 tetrahydropyridine analogs 1 methyl 4 2 thienyl 1 2 3 6 tetrahydropyridine and 1 methyl 4 3 thienyl 1 2 3 6 tetrahydropyridine on monoamine oxidase in vitro and on dopamine in mouse brain. Journal of Pharmacology & Experimental Therapeutics 240(2): 415-420, 1987

Comparison of the effects of two 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs, 1-methyl-4-(2-thienyl)-1,2,3,6-tetrahydropyridine and 1-methyl-4-(3-thienyl)-1,2,3,6-tetrahydropyridine, on monoamine oxidase in vitro and on dopamine in mouse brain. Journal of Pharmacology and Experimental Therapeutics 240(2): 415-420, 1987

Marked 1 methyl 4 phenyl 1 2 3 6 tetrahydropyridine induced dopaminergic neurotoxicity in black mice with high cerebral 1 methyl 4 phenyl 1 2 3 6 tetrahydropyridine monoamine oxidase b activity. Experientia 42(6): 700, 1986